MX2007004660A - Uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-(piridin-3- il)pirimidin-2-ilamino)fenil]-benzamida para inhibir el receptor de tirosina cinasa c-fms. - Google Patents

Uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-(piridin-3- il)pirimidin-2-ilamino)fenil]-benzamida para inhibir el receptor de tirosina cinasa c-fms.

Info

Publication number
MX2007004660A
MX2007004660A MX2007004660A MX2007004660A MX2007004660A MX 2007004660 A MX2007004660 A MX 2007004660A MX 2007004660 A MX2007004660 A MX 2007004660A MX 2007004660 A MX2007004660 A MX 2007004660A MX 2007004660 A MX2007004660 A MX 2007004660A
Authority
MX
Mexico
Prior art keywords
fms
compound
csf
microglial
methyl
Prior art date
Application number
MX2007004660A
Other languages
English (en)
Spanish (es)
Inventor
Andrea Louis Dewar
Timothy Peter Hughes
Alan Bruce Lyons
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of MX2007004660A publication Critical patent/MX2007004660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2007004660A 2004-10-18 2005-10-17 Uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-(piridin-3- il)pirimidin-2-ilamino)fenil]-benzamida para inhibir el receptor de tirosina cinasa c-fms. MX2007004660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61974404P 2004-10-18 2004-10-18
PCT/AU2005/001602 WO2006042362A1 (en) 2004-10-18 2005-10-17 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms

Publications (1)

Publication Number Publication Date
MX2007004660A true MX2007004660A (es) 2007-10-17

Family

ID=36202610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004660A MX2007004660A (es) 2004-10-18 2005-10-17 Uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-(piridin-3- il)pirimidin-2-ilamino)fenil]-benzamida para inhibir el receptor de tirosina cinasa c-fms.

Country Status (19)

Country Link
US (1) US20080255139A1 (cg-RX-API-DMAC7.html)
EP (1) EP1804800B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008516898A (cg-RX-API-DMAC7.html)
KR (1) KR20070083705A (cg-RX-API-DMAC7.html)
CN (1) CN101035535A (cg-RX-API-DMAC7.html)
AT (1) ATE492277T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005297321A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0517083A (cg-RX-API-DMAC7.html)
CA (1) CA2580976A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005025514D1 (cg-RX-API-DMAC7.html)
IL (1) IL182419A0 (cg-RX-API-DMAC7.html)
MA (1) MA28946B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007004660A (cg-RX-API-DMAC7.html)
NO (1) NO20072501L (cg-RX-API-DMAC7.html)
NZ (1) NZ554009A (cg-RX-API-DMAC7.html)
RU (1) RU2007118420A (cg-RX-API-DMAC7.html)
TN (1) TNSN07141A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006042362A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200702316B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058968A2 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
EP3246046A4 (en) * 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds

Also Published As

Publication number Publication date
RU2007118420A (ru) 2008-11-27
ATE492277T1 (de) 2011-01-15
MA28946B1 (fr) 2007-10-01
JP2008516898A (ja) 2008-05-22
DE602005025514D1 (de) 2011-02-03
WO2006042362A1 (en) 2006-04-27
KR20070083705A (ko) 2007-08-24
BRPI0517083A (pt) 2008-09-30
TNSN07141A1 (en) 2008-11-21
CN101035535A (zh) 2007-09-12
EP1804800A4 (en) 2008-03-19
NZ554009A (en) 2010-09-30
CA2580976A1 (en) 2006-04-27
US20080255139A1 (en) 2008-10-16
IL182419A0 (en) 2007-09-20
EP1804800A1 (en) 2007-07-11
ZA200702316B (en) 2008-09-25
EP1804800B1 (en) 2010-12-22
AU2005297321A1 (en) 2006-04-27
NO20072501L (no) 2007-05-15

Similar Documents

Publication Publication Date Title
Yun et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR–MET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven NSCLC
Zhao et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias
Kharas et al. Phosphoinositide 3-kinase signaling is essential for ABL oncogene–mediated transformation of B-lineage cells
US10314834B2 (en) Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation
Wlodarski et al. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum
EA027654B1 (ru) Комбинация панобиностата и руксолитиниба при лечении рака, такого как миелопролиферативное новообразование
US20080219977A1 (en) Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US20260053761A1 (en) Use of thyromimetics for the treatment of cancer
AU2021348477B2 (en) Csf1r kinase inhibitor and use thereof
Park et al. PRPF4 is a novel therapeutic target for the treatment of breast cancer by influencing growth, migration, invasion, and apoptosis of breast cancer cells via p38 MAPK signaling pathway
KR20210019422A (ko) 암 치료 방법
EP3479843A1 (en) Use of nox inhibitors for treatment of cancer
Glaser et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families
US20250361307A1 (en) Combination therapies for treating hyperproliferative disorders
US20220025036A1 (en) Use of il-1beta binding antibodies
US20050171182A1 (en) Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
JP2018511605A (ja) 慢性骨髄性白血病癌幹細胞の成長抑制用または増殖抑制用の組成物、及びそのスクリーニング方法
EP1804800B1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl¨-benzamide to inhibit the tyrosine kinase receptor c-fms
US20190240225A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
US11648255B2 (en) Inhibitors for treatment of hematological malignancies
RU2415672C2 (ru) Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
WO2017090699A1 (ja) ピラジンカルボキサミド化合物を有効成分とするがん免疫治療用医薬組成物、及び/又は、免疫活性化用医薬組成物
Roby Response to Stress by the Tumor Microenvironment
EP4561704A2 (en) Use of glycogen metabolism inhibitors for the treatment of cancer
Hedvat Targeting JAK/STAT Signaling for Solid Tumor Therapy